Fatal Invasive Pulmonary Aspergillosis Associated with Adalimumab Therapy
an elevated C-reactive protein and leukocytosis. Within 12 hours after admission, respiratory insufficiency developed. Ventilatory support was needed to achieve adequate oxygenation. A bronchoscopy was performed, which showed white coverings, histologically corresponding to invasive aspergillosis. The situation was complicated by a pre-existing renal insufficiency and a chronic metabolic acidosis.
Despite intensive care treatment including antibiotics, fungostatic therapy, vasoactive drugs and hemofiltration the patient died two days after admission.
Our patient had no known risk factors associated with invasive aspergillosis.
She had no neutropenia, nor did she take any corticosteroids or other immunosuppressive drugs during the twelve months before the infection. She had been a non-smoker, had not used marijuana, and had not had a prior influenza infection or any known exposure to aspergillus. Therefore, an association with the TNF-α blocker therapy is highly probable.
Infections are a well known complication of all TNF-α antibodies. In a recent review Tsiodras and colleagues have summarized fungal infections after TNF-α blockade therapy. Out of 281 cases of invasive fungal infections 11 cases (4%) were associated with adalimumab (compared to 80 % associated with infliximab and 16% with etanercept). 2 For the two cases with aspergillosis on adalimumab no further data was available in this review. 2 Whereas invasive pulmonary aspergillosis is associated with infliximab therapy 3 it has to our best knowledge not been described for other anti-TNF-α antibodies so far. TNF-α inhibition can increase susceptibility to invasive fungal infections trough inhibition of interferon-γ production, a decreased expression of pattern-recognition receptors and trough leukocyte apoptosis. 4 With this fatal case we would like to support the observations that the use of antibodies against TNF-α including the new agents like adalimumab increases the risk of serious opportunistic infections trough inhibition of an adequate TNF-α response. Clinicians should have a high level of suspicion for fast diagnosis and treatment of fungal disease in patients with TNF-α blockers.
